Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouYou approved the lab sample, signed the scale-up agreement, and booked the first production slot for your body wash or body lotion. Then a fragrance accord gets discontinued, a botanical extract supplier changes, or…
You approved the lab sample, signed the scale-up agreement, and booked the first production slot for your body wash or body lotion. Then a fragrance accord gets discontinued, a botanical extract supplier changes, or your pump supplier switches resin — and someone in the email thread asks: “Do we need to re-run stability?” In most body care scale-ups, that question has no written owner. The result is either a launch that stalls for six weeks over an unclear decision, or worse, a product that ships with an unresolved shelf-life risk nobody formally accepted. This guide explains how to structure the decision inside your scale-up agreement so that “who decides” is answered before the first bulk batch, not after.
Stability retesting after a change is rarely a technical mystery. A new botanical extract, a different preservative, a reformulated fragrance, or a new bottle resin will usually change the material’s chemistry, microbial load, or interaction with the pack. The harder question is governance: who has the authority to say “retest is not required,” and who carries the consequence if that call is wrong.
In practice, three decisions have to be separated and assigned in writing:
The commercial reality is that the manufacturer knows the process and the raw material; the brand owner owns the finished-product claim and, in most markets, the regulatory responsibility for the product’s safety and labelling. That asymmetry is why the authority to close a stability question should sit with the brand’s quality/regulatory function, informed by the manufacturer’s assessment — not delegated entirely to the filler, and not micromanaged by marketing.
Attach a table like the one below as an appendix to your supply or quality agreement. If it is not written down, the default is that the party with the loudest email decides — which is a poor quality system.
| Decision | Who decides (accountable) | Who must be consulted | Evidence filed |
|---|---|---|---|
| Is this change a retest trigger? | Brand QA / Regulatory (product owner) | Manufacturer QA, third-party lab | Signed change assessment form with trigger classification |
| Scope of the retest | Brand QA with manufacturer R&D | Testing lab, packaging supplier | Approved protocol listing tests, timepoints, conditions, acceptance criteria |
| Shelf-life claim after the change | Brand owner (regulatory / Responsible Person role) | Safety assessor, manufacturer | Updated safety/product information file or written justification for retaining the claim |
| Release or hold of affected batches | Manufacturer QA for release; brand for market hold | — | Batch record, COA, deviation and disposition report |
| Re-signing the Golden sample | Joint: manufacturer quality + R&D, countersigned by brand | — | New Golden sample bound to formula version, process version and packaging version |
| Cost and lead-time impact | Commercial owners per the agreement | Project management | Signed variation or purchase order referencing the change request |
| Escalation if no agreement within X days | Named escalation contacts on both sides | — | Escalation log entry with dates |
Informational only, not legal advice. Regulatory obligations vary by market and by who holds the Responsible Person or distributor role.
Body care is unforgiving here because most formats are water-based, surfactant-heavy, or packaged in pumps and tubes that interact with the formula. A useful agreement defines default classifications so the same argument is not repeated for every change order.
| Change in your body care line | Default status | Minimum evidence before release |
|---|---|---|
| Botanical extract supplier change (e.g., aloe, green tea, oat in a body lotion) | Retest required | Stability protocol plus microbial specification review and preservative efficacy re-evaluation |
| Preservative system or preservative supplier change | Retest + preservative challenge test | Challenge test report, micro spec review, water-activity rationale |
| Fragrance version or fragrance house change | Retest required | IFRA/allergen declaration for the new version, fragrance–plastic compatibility data |
| Thickener or rheology modifier substitution | Retest required | Viscosity and pH trend at defined timepoints, sensory proxy comparison |
| Colorant change | Retest required | Color and light-exposure stability data, label claim review |
| Primary pack supplier, resin or decoration change (bottle, pump, cap, gasket) | Compatibility test required | Real-bulk compatibility report on the finished pack including decoration |
| Process version change (mixing speed, temperature, homogenisation time) | Assess — frequently escalates to retest | Process validation record, bridge data against the existing stability baseline |
| Manufacturing site or major equipment change | Assess + bridge | Method bridge report, first-batch comparison against the Golden sample |
| Bulk hold-time extension | Retest (microbiological) | Hold-time protocol, micro re-test results for the extended period |
| Artwork or carton copy change only | No stability retest | Label review sign-off and claims substantiation file |
A clause that says “stability will be re-evaluated” is not operational. Define the deliverables. For a body wash or body lotion, a defensible re-evaluation after a material change normally covers:
| Phase | Typical timing | Buyer action | Manufacturer action | Evidence output |
|---|---|---|---|---|
| Notification and classification | Week 0–1 | Confirm trigger classification and scope | Issue change request with material and process details | Signed change assessment form |
| Impact assessment | Week 1–2 | Decide retest scope with QA | Review specification, method bridge, Golden sample status | Approved protocol and test plan |
| Packaging compatibility | Week 2–6 | Confirm pack direction and decoration | Fill real bulk into real pack, run cycling and leak checks | Compatibility report with photographs |
| Stability and micro testing | Week 2–12+ | Approve acceptance criteria | Run timepoints, monitor trend against baseline | Interim and final stability report, micro results |
| Label and claims review | Week 3–5 | Confirm no claim now exceeds the evidence | Provide updated INCI, allergen and specification data | Label review sign-off, updated claim support file |
| Pilot run | Week 6–10 | Approve pilot batch against Golden | Produce pilot, compare against baseline | Pilot batch record and comparison report |
| Documentation handover | Before first commercial release | Verify the document pack is complete | Compile COA, SDS, stability, micro, compatibility, batch records | Complete technical file with version control |
A fastest-safe path is possible when the change is limited to decoration or artwork, or when the pack is unchanged and only a colourant shifts within an already-tested family. The standard path applies whenever the preservative system, fragrance, botanical source, or primary pack changes — compressing those is how launches get recalled rather than delayed.
Share the change notification form and reference number for this change.
Confirm whether the change is classified as a stability retest trigger.
List the raw material, supplier, grade and version affected.
State whether the INCI declaration on the label changes.
Provide the current specification sheet and COA for the new material.
Attach the SDS for the new material with the revision date.
Confirm whether the preservative system requires a new challenge test.
Provide the stability protocol with timepoints, conditions and acceptance criteria.
Confirm the storage conditions and duration for bulk hold-time validation.
Identify every pack component affected: bottle, pump, cap, gasket, decoration, label.
Attach the packaging compatibility report using real bulk in the final pack.
Provide photographs of the pack after cycling, inverted and side-lay storage.
Confirm the fragrance version number used in the compatibility test.
Provide the IFRA and allergen declaration matched to that fragrance version.
State whether any on-pack claim now exceeds the available evidence.
Provide the updated claim support file if any claim wording changes.
Confirm the Golden sample status and whether it must be re-signed.
Attach the impact assessment for the existing shelf-life claim.
Provide retained sample records under controlled storage conditions.
List the documents to be delivered at final handover, with version numbers.
Confirm the named QA contact accountable for closure on your side.
Confirm the escalation contact if the assessment is not closed on time.
Only as an input, not as a conclusion. Ask for the written impact assessment showing what was evaluated — raw material chemistry, microbial load, pack interaction and the existing shelf-life claim — then have your own quality or regulatory owner sign the decision. The brand carries the market-facing consequence if a shelf-life claim fails.
Decide this in the agreement, not case by case. A common structure is that the party initiating the change bears the cost, with a schedule of standard test packages and prices attached to the agreement. What matters more than the split is that cost allocation never becomes the reason a test is skipped.
Packaging compatibility is usually the shorter pole, often a few weeks. Full stability with real-time timepoints runs far longer, so most agreements allow release on interim data plus a committed continued study — with a written rule for what happens if later timepoints fail.
Yes. Same INCI name does not mean same chemistry, impurity profile, microbial load or odour. Grade, processing and origin can shift viscosity, colour and preservative demand. Treat it as a change and let the assessment decide the depth of testing.
Accelerated and cycling data support a decision; they do not replace the ongoing monitoring of retained commercial samples under controlled conditions across the shelf life. Build the retention plan into the agreement at the same time as the retest clause.
If you are preparing a scale-up agreement, or renegotiating one after a supplier change, bring the specifics: target markets, SKU list and formats, positioning, packaging direction and your timeline target. That information turns a general enquiry into a scoped proposal with a defined change-control and stability plan attached.